

Estudio Propio: **EXPERTO EN ANTICONCEPCIÓN PARA MATRONAS**

Código Plan de Estudios: **EP53**

Año Académico: **2021-2022**

ESTRUCTURA GENERAL DEL PLAN DE ESTUDIOS:							
CURSO	Obligatorios		Optativos		Prácticas Externas	Memoria/ Proyecto	Créditos
	Créditos	Nº Asignaturas	Créditos	Nº Asignaturas	Créditos	Créditos	
1º	18	1					18
2º							
3º							
ECTS TOTALES	18	1					18

PROGRAMA TEMÁTICO:				
ASIGNATURAS OBLIGATORIAS				
Código Asignatura	Curso	Denominación	Carácter OB/OP	Créditos
706278	1	MANEJO DE LA ANTICONCEPCIÓN PARA MATRONAS	OB	18

Carácter: OB - Obligatoria; OP – Optativa

GUÍA DOCENTE

Año académico	2021-2022	
Estudio	Experto en Anticoncepción para Matronas	
Nombre de la asignatura	MANEJO DE LA ANTICONCEPCIÓN PARA MATRONAS	
Carácter (Obligatoria/Optativa)	Obligatoria	
Créditos (1 ECTS=25 horas)	18	
Modalidad (elegir una opción)		Presencial
		Semipresencial
		On-line
	x	A distancia
Profesor/a responsable	M ^a Jesús Cancelo Hidalgo	
Idioma en el que se imparte	Castellano	

PROFESORES IMPLICADOS EN LA DOCENCIA

MACARENA QUESADA MORENO
 ENRIQUETA BARRANCO CASTILLO
 ESTHER DE LA VIUDA GARCIA
 EZEQUIEL PÉREZ CAMPOS
 FÁTIMA LEÓN LARIOS
 FRANCISCA MARTÍNEZ SAN ANDRÉS
 INMACULADA PARRA RIBES
 ISABEL RAMÍREZ POLO
 JOAQUÍN GARCÍA CERVERA
 JOSÉ M^a MARI JUAN
 JOSÉ VICENTE GONZÁLEZ
 M^a JESÚS ALONSO LLAMAZARES
 M^a JESÚS CANCELO HIDALGO
 M^a JOSÉ PUENTE MARTINEZ
 MARTA CORREA RANCEL
 MARTA LEGORBURU
 MODESTO REY NOVOA
 NICOLÁS MENDOZA LADRÓN DE GUEVARA
 NURIA PARERA JUNYENT
 PALOMA LOBO ABASCAL
 RAFAEL SÁNCHEZ BORREGO
 SERGIO HAIMOVICH SEGAL
 SILVIA TAPIADOR ALBERTOS

DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)	
Número de horas presenciales/on-line asistencia profesor/a	150
Número de horas de trabajo personal del estudiante	300
Total horas	450

CONTENIDOS (Temario)
<p>SITUACIÓN ACTUAL DE LA ANTICONCEPCIÓN EN ESPAÑA Y EUROPA MITOS EN ANTICONCEPCIÓN ANATOMÍA DEL APARATO GENITAL FEMENINO Y MASCULINO PRINCIPIOS ACTIVOS EN ANTICONCEPCIÓN Y REPRODUCCIÓN PAPEL DE LAS HORMONAS EN LA SEXUALIDAD REGULACIÓN DEL CICLO MENSTRUAL FARMACOCINÉTICA Y FARMACODINAMIA DE AH HISTORIA DE LA ANTICONCEPCIÓN MÉTODOS NATURALES Y MÉTODOS BARRERA ANTICONCEPCIÓN HORMONAL COMBINADA ANTICONCEPCIÓN CON SOLO GESTÁGENOS ANTICONCEPCIÓN INTRAUTERINA ANTICONCEPCIÓN DE URGENCIA DOBLE MÉTODO ANTICONCEPCIÓN QUIRÚRGICA FEMENINA Y MASCULINA GENERALIDADES SOBRE LOS BENEFICIOS DE LOS MÉTODOS ANTICONCEPTIVOS INTERACCIONES MEDICAMENTOSAS EN TRATAMIENTOS HABITUALES CME. CONFERENCIA DE CONSENSO SEC ASESORAMIENTO ANTICONCEPTIVO (Requisitos para la anticoncepción) ASESORAMIENTO ANTICONCEPTIVO EN ITS ASESORAMIENTO ANTICONCEPTIVO EN LA ADOLESCENCIA ASESORAMIENTO ANTICONCEPTIVO EN LA PERIMENOPAUSIA ASESORAMIENTO ANTICONCEPTIVO EN POSTPARTO Y LACTANCIA ASESORAMIENTO ANTICONCEPTIVO POST-ABORTO. ESTRATEGIAS PARA EVITAR ABORTOS DE REPETICIÓN ASESORAMIENTO ANTICONCEPTIVO EN ALTERACIONES DE LA HEMOSTASIA Y PATOLOGÍA CARDIOVASCULAR ASESORAMIENTO ANTICONCEPTIVO EN ENDOCRINOPATÍAS ASESORAMIENTO ANTICONCEPTIVO EN MUJERES CON OBESIDAD EDUCACIÓN MATERNAL: ASESORAMIENTO ANTICONCEPTIVO LA ATENCIÓN A LA SALUD SEXUAL Y REPRODUCTIVA: SEXUALIDAD EN EMBARAZO Y PUERPERIO ATENCIÓN EN SITUACIONES DE VIOLENCIA DE GÉNERO DIVERSIDAD CULTURAL Y SSR Y ANTICONCEPCIÓN ANTICONCEPCIÓN Y CALIDAD DE VIDA CASOS CLÍNICOS</p>

COMPETENCIAS ESPECÍFICAS (indicar un mínimo de tres y máximo de cinco)
<p>-EL ALUMNO ESTARÁ CAPACITADO PARA ASESORAR A LA USUARIA SOBRE LOS RIESGOS, BENEFICIOS Y POSIBLES EFECTOS SECUNDARIOS EN ANTICONCEPCIÓN. -EL ALUMNO ESTARÁ CAPACITADO/A PARA RESOLVER LAS DUDAS MÁS FRECUENTES SOBRE</p>

ANTICONCEPCIÓN A LA USUARIA DE ANTICONCEPCIÓN.

- EL ALUMNO ESTARÁ CAPACITADO/A PARA REALIZAR LA ANAMNESIS, HISTORIA CLÍNICA Y EXPLORACIÓN EN ANTICONCEPCIÓN

-CAPACITADO/A PARA DERIVAR A CONSULTA DE ATENCIÓN PRIMARIA A LAS USUARIAS PARA PRESCRIPCIÓN DE MÉTODO ANTICONCEPTIVO EN MUJERES DE BAJO RIESGO/ RIESGO MEDIO/ RIESGO ALTO

EVALUACIÓN

EXAMEN TIPO TEST

BIBLIOGRAFÍA

United Nations Population Division. Department of Economic and Social Affairs. World Contraceptive Use 2015

Accesible en

<http://www.un.org/en/development/desa/population/publications/pdf/family/trendsContraceptiveUse2015Report.pdf>

United Nations Population Division. Department of Economic and Social Affairs. World Contraceptive Use 2018

Accesible en :

<http://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2018.shtml>

Contraception Atlas Accesible en: <https://www.contraceptioninfo.eu/node/7>

Who Model List of Essential Medicines 20th List (March 2017) Accesible en:

https://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1

ECEC accesible en:<http://www.ec-ec.org/emergency-contraception-in-europe/emergency-contraception-availability-in-europe/> (31-1-2017)

ECEC accesible en: <http://www.ec-ec.org/emergency-contraception-in-europe/country-by-country-information-2/> (19-12-2018)

An update on access to emergency contraception in European Union Countries ECEC April 2016 Accesible en : <http://www.ec-ec.org/custom-content/uploads/2016/04/UPDATE-Access-to-EC-in-EU-countries-ECEC-April2016.pdf>

Sedgh G. Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet 2016; 388: 258–67

Bearak J. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health 2018; 6: e380–89

The World abortion Laws 2019. Accesible en: <http://worldabortionlaws.com>

World Health Organization. Reproductive Health and Research., World Health Organization. Family and Community Health. Selected practice recommendations for contraceptive use. World Health Organization, Reproductive Health and Research, Family and Community Health; 2005. Apter D,

Zimmerman Y, Beekman L, Mawet M, Maillard C, Foidart J-M, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. *Eur. J. Contracept. Reprod. Heal. Care* [Internet]. 2017 Jul 4 [cited 2018 Nov 23];22(4):260–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28641030> Bastianelli C, Farris M, Rosato E, Brosens I, Benagiano G. Pharmacodynamics of combined estrogen-progestin oral contraceptives: Effects on metabolism. *Expert Rev. Clin. Pharmacol.* [Internet]. 2016 Dec 15 [cited 2017 Jan 24];17512433.2017.1271708. Available from: <https://www.tandfonline.com/doi/full/10.1080/17512433.2017.1271708> Dinger J, Minh T Do, Buttman N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. *Obstet. Gynecol.* [Internet]. 2011 Jan [cited 2018 Nov 18];117(1):33–40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21213475> Duijkers IJM, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study. *Eur. J. Contracept. Reprod. Health Care* [Internet]. 2015 [cited 2018 Nov 23];20(6):476–89. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26394847> Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. *Contraception* [Internet]. 2010 Oct [cited 2018 Nov 18];82(4):314–23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20851224> Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. *Cochrane Database Syst. Rev.* [Internet]. 2013 Aug 1 [cited 2018 Nov 18];(8):CD003989. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23904209> Gourdy P, Guillaume M, Fontaine C, Adlanmerini M, Montagner A, Laurell H, et al. Estrogen receptor subcellular localization and cardiometabolism. *Mol. Metab.* [Internet]. Elsevier; 2018 Sep 1 [cited 2018 Nov 23];15:56–69. Available from: <https://www.sciencedirect.com/science/article/pii/S2212877818302771> Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? *Eur. J. Contracept. Reprod. Heal. Care* [Internet]. 2017 Jul 4 [cited 2018 Nov 18];22(4):245–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28902531> Jusko WJ. Clarification of contraceptive drug pharmacokinetics in obesity. *Contraception* [Internet]. 2017a Jan [cited 2018 Nov 18];95(1):10–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27542520> Jusko WJ. Perspectives on variability in pharmacokinetics of an oral contraceptive product. *Contraception* [Internet]. 2017b Jan [cited 2018 Nov 18];95(1):5–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27475034> Lackie E, Fairchild A. The birth control pill, thromboembolic disease, science and the media: a historical review of the relationship. *Contraception*. 2016. De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G. Hormonal contraceptives: pharmacology tailored to women's health. *Hum. Reprod. Update* [Internet]. 2016 Sep [cited 2017 Jan 24];22(5):634–46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27307386> London A, Jensen JT. Rationale for eliminating the hormone-free interval in modern oral contraceptives. *Int. J. Gynaecol. Obstet.* [Internet]. 2016 Jul [cited 2018 Nov 18];134(1):8–12. Available from: <http://doi.wiley.com/10.1016/j.ijgo.2015.10.028> Mueck AO, Sitruk-Ware R. Norgestrel acetate, a novel progestogen for oral contraception. *Steroids* [Internet]. 2011 May [cited 2018 Nov 18];76(6):531–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21335021> Narayan P, Ulloa-Aguirre A, Dias JA. Gonadotropin Hormones and Their Receptors. *Yen Jaffe's Reprod. Endocrinol.* [Internet]. Content Repository Only!; 2019 Jan 1 [cited 2018 Nov 23];25– 57.e15. Available from: <https://www.sciencedirect.com/science/article/pii/B9780323479127000020> Nelson AL. Transdermal contraception methods: today's patches and new options on the horizon. *Expert Opin. Pharmacother.* [Internet]. 2015 Apr 13 [cited 2018 Nov 18];16(6):863–73. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25800084> Regidor P-A. Clinical relevance in present day hormonal contraception. *Horm. Mol. Biol. Clin. Investig.* [Internet]. 2018a Oct 26 [cited 2018 Nov 18];0(0). Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30367791> Regidor P-A. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. *Oncotarget* [Internet]. 2018b Oct 2 [cited 2018 Nov 16];9(77):34628–38. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30349654> Sitruk-Ware R, Nath A. The use of newer progestins for contraception. *Contraception* [Internet]. 2010 Nov [cited 2018 Nov 18];82(5):410–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20933114> Sitruk-Ware R, Nath A. Metabolic effects of

- contraceptive steroids. *Rev. Endocr. Metab. Disord.* [Internet]. 2011 Jun 3 [cited 2018 Nov 18];12(2):63–75. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21538049> Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. *Best Pract. Res. Clin. Endocrinol. Metab.* [Internet]. 2013a Feb [cited 2018 Nov 18];27(1):13–24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23384742> Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. *Best Pract. Res. Clin. Endocrinol. Metab.* [Internet]. 2013b Feb [cited 2018 Nov 16];27(1):13–24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23384742> Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17 β -estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. *Contraception* [Internet]. Elsevier; 2013 Jun 1 [cited 2018 Nov 18];87(6):706–27. <http://www.who.int/reproductivehealth/en/>. OMS. 5th Edition MEC http://apps.who.int/iris/bitstream/10665/205016/1/WHO_RHR_15.07_spa.pdf?ua=1 Resumen ejecutivo de la 5ª ed, Criterios médicos de elegibilidad para la elección de método anticonceptivo http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1. Medical Eligibility Criteria for contraceptive use  <http://www.who.int/rhl/es/> OMS. La biblioteca de Salud Reproductiva <http://www.who.int/rhl/fertility/contraception/es/> OMS. La biblioteca de Salud Reproductiva. Contracepción http://www.who.int/rhl/fertility/contraception/mec_story/es/ OMS. La biblioteca de Salud Reproductiva. Criterios de elegibilidad médica de la OMS para el uso de anticonceptivos http://www.fsrh.org/pages/clinical_guidance.asp FSRH is a faculty of the Royal College of Obstetricians and Gynaecologists established in 1997 as the Faculty of Sexual and Reproductive Healthcare. <https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html> US Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2016
- 1 -Abrams LS, Skee DM, Natarajan J, Hutman W, Wong FA. Tetracycline HCL does not affect the pharmacokinetics of a contraceptive patch. *Int J GynaecolObstet* 2000; 70(Suppl. 1): 57–58.
 - 2 -AIDS info. Guidelines for the use of antiretroviral agents in HIV-1 Infected adults and adolescents. <https://aidsinfo.nih.gov/guidelines> on 12/1/2018
 - 3 -Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, et al. The effect of rifampicin on the pharmacokinetics of ethinylestradiol in women. *Contraception* 1980;21:135-143.
 - 4-Back DJ, Grimmer SfM, Orme MLE, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. *Br J Clin Pharmacol* 1988; 25: 527–532.
 - 5-Bainton R. Interaction between antibiotic therapy and contraceptive medication. *Oral Surg Oral Med Oral Pathol Oral RadiolEndod* 1986; 61: 453–455.
 - 6-Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. *Clin Pharmacol Ther* 1999; 65:428–438.
 - 7-Berry-Bibee EN, et al. Co-administration of St. John’s and hormonal contraceptives: a systematic review. *Contraception*;94(2016): 668-677.
 - 8-Berry-Bibee EN, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. *Contraception Dec* ; 94(2016): 650-667.
 - 9-- Bollen M. Use of antibiotics when taking the oral contraceptive pill. *Aust Fam Physician* 1995; 24: 928–929.
 - 10 –Instituto Catalán de la Salud. Comité de evaluación de nuevos Medicamentos. Ulipristal.– CANM número 8, Octubre 2010.
 - 11- Christian Manzardo , Montserrat Tuset, Jose M. Miró , Jose M. Gatell.. Interacciones graves o potencialmente letales entre antirretrovirales y otros medicamentos. *Enfermedades infecciosas y microbiología clínica*. Vol 33 ;Nº 17 (2015): 435-504
 - 12-Csemiczky G, Alvendal C, Landgren BM. Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with fluoroquinolone (ofloxacin).

AdvContracept 1996; 12: 101–109.

13- Chappell CA, Lasmorde N, Nakalema S et al. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. *AIDS* 2017 Sep 10;31(14):1965-1972.

14- Chappell C. Efavirenz — but not nevirapine — based antiretroviral therapy significantly reduces etonogestrel concentrations among HIV-positive women using subdermal contraceptive implants. *Contraception* 2016 94(4):390

15-Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring Nuvaring with oral amoxicillin or doxycycline in two randomised trials. *Clin Pharmacokinet* 2005; 44: 429–438

16-Donley TG, Smith RF, Roy B. Reduced oral contraceptive effectiveness with concurrent antibiotic use: a protocol for prescribing antibiotics to women of childbearing age. *Compendium* 1990; 11: 392–396.

17-Dossetor J. Drug interactions with oral contraceptives. *BMJ* 1984; 4: 467–468.

18 -Edelman A, Gallo MF, Jensen JT, Nichols MD, Grimes DA. Continuous or extended cycles vs. cyclic use of combined hormonal contraceptives for contraception. *Cochrane Database System Rev* 2005, 3:CD004695. DOI: 10.1002/14651858.CD004695.pub2

19 -Faculty of Family Planning and Reproductive Health Care. Drug Interactions with Hormonal Contraception (January 2011). Faculty of Sexual and Reproductive Healthcare – Clinical Effectiveness Unit, January 2011. [accessible online en www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf,

20 -Faculty of Family Planning and Reproductive Health Care. Clinical Guidance: Drug Interactions with Hormonal Contraception (January 2018)

21-García P, Martínez F, Pintor A, Caelles N e Ibañez J. Guía Sandoz de utilización de medicamentos. Anticonceptivos hormonales. Uni Granada. 2006:28-34

22-Joint Formulary Committee. *British National Formulary (BNF)*. 2010

23-Joshi JV, Joshi UM, Sankolli GM, Gupta K, Rao AP, Hazari K, et al. A study of interaction of a low-dose contraceptive with anti-tubercular drugs. *Contraception* 1980; 21: 617–629.

24- Jusko WJ. Perspectives on variability in pharmacokinetics of an oral contraceptive product. *Contraception* 95(2017):5-9

25-Katabian L. IX Congreso AMADA Obt –Gin 2012. Córdoba. Argentina . Disponible en https://www.youtube.com/watch?v=_BIZNLo0CuM

26- Kourtis AP, Mirza A. Contraception for HIV- Infected Adolescents. *Pediatrics*. 2016 Sep; 138(3). Pii:e20161802. Doi:10.1542/peeds.2016-1892.

27- Landolt NK, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. *J Acquir Immune Defic Syndr*. 2013;62(5):534–539.

28- Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. *Contraception* 95(2017) 571-577

29-LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, et al. Effects of rifabutin and rifampicin on pharmacokinetics of ethinylestradiol and norethindrone. *J Clin Pharmacol* 1998; 38: 1042–1050.

30- Leticee N et al. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. *Contraception* 85 (2012) 425–427

31- Martín Auriol E, De la Cruz Cortés JP, González Correa JA. Antibióticos y anticonceptivos: ¿una interacción relevante? *Actualidad en Farmacología y Terapéutica*. Marzo 2011, vol9 nº 1:43-45.

32-Meadows M. Preventing serious Drug Interactions. *FDA Consumer*, jul/Aug 2004, vol.38 Issue 4, p 12-17,6p,3c.

33- Menon S, Riese R Wang R et al. Evaluation of the effect of Tofacitinib on the pharmacokinetics of oral

- contraceptive steroids in healthy female volunteers. *Clinical Pharmacology in drug Development* 2016,5(5):336-342
- 34- Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/ norethindrone when administered concurrently to HIV-infected women. *J Acquir Immune Defic Syndr*. 2002;29(5):471–477
- 35- Moltó J. Guía de interacciones medicamentosas de interés en el paciente infectado por el VIH, 2ª Edición 2016. Fundación lucha contra el SIDA.
- 36- Murphy AA, Zacur HA, Charace P, Burkman RT. The effect of tetracycline on level of oral contraceptives. *Am J ObstetGynecol* 1991; 164: 28–33.
- 37- Nanda K, Delany-Moretlwe S, Dubé K, et al. Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. *AIDS*. 2013;27(suppl 1):S17–S25
- 38- Neely JL, Abate M, Swinker M, D'Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. *ObstetGynecol* 1991; 77: 416–420.
- 39- OMS 2010 World Health Organization. Medical eligibility criteria for contraceptive use – 4th ed. 2010.
- 40- OMS 2015 World Health Organization. Medical eligibility criteria for contraceptive use – 5th ed. 2015.
- 41- Reimers A et al. . Interactions between hormonal contraception and antiepileptic drugs: Clinical and mechanistic considerations. *Seizure* ; 28 (2015): 66-70.
- 42- Reitelr L, Nakken KO. Contraception for women taking antiepileptic drugs. *Tidsskr Nor Laegeforen*. 2016 Jan 12;136(1):32-4.
- 43- Scholten PC, Droppert RM, Zwinkels MGL, Moesker HL, Nauta JJP, Hoepelman IM. No interaction between ciprofloxacin and an oral contraceptive. *Antimicrob Agents Chemother* 1998; 42: 3266–3268.
- 44- Schwartz J, Hunt T, Smith WB, Wong P, Larson P, Crumley T, et al. The effect of etoricoxib on the pharmacokinetics or oral contraceptive in healthy participants. *J Clin Pharmacol* 2009; 49: 807–815.
- 45- Sidhu J, Job S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. *Br J Pharmacol* 2005; 61: 191–199.
- 46- Simmons KB et al . Effect of concurrent vaginal miconazole treatment on the absorption and exposure of Nesterone and Etilnil estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. *Contraception* 97 (2018) 270-276.
- 47- Scarsi et al. drug-drug interactions, Effectiveness, and safety of hormonal contraceptives in women living with HIV. *Drug Saf*. 2016 Nov; 39(11): 1053-1072.
- 48- Sociedad Española de Farmacia Hospitalaria: SEFH. Introducción a las interacciones farmacológicas. 1ª Ed. 2014. Versión digital disponible en: www.sefh.es
- 49- .Stuart GS, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. *J Acquir Immune Defic Syndr*. 2011;58(2):e40–e43.
- 50- Sujatha Menon, Richard Riese, Ronnie Wang, et al. Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. *Clinical Pharmacology in Drug Development* 2016, 5(5): 336–342.
- 51- Torres Serna C. Anticonceptivos hormonales y su interacción con otros medicamentos. ANTICONCEPCIÓN EN SITUACIONES ESPECIALES. 2006. Cap 34
- 52- University of Liverpool. HIV drug-interactions. www.hiv-druginteractions.org/Charts reviewed October 2018.
- 53- Hongjian Zhang, Donghui Cui, Bonnie Wang et al. Pharmacokinetic Drug Interactions Involving 17 α -Ethinylestradiol. A New Look at an Old Drug. *Clin Pharmacokinet* 2007; 46 (2): 133-157.
- 54- Zhang H et al. Pharmacokinetic Drugs Interactions Involving 17 alpha-Ethinylestradiol: A new look at an

Old Drug. Clin Pharmacokinet 46(2)2007:133-157.

55-Zuccherro F, Hogan M. Pocket Guide to Evaluation of Drug Interactions. American Pharmacists Association, 5ª Ed. 2004, FÁRMACOS UTILIZADOS EN LA INDUCCIÓN DEL ABORTO FARMACOLÓGICO

Flores, J.; Armijo, J.A.; Mediavilla, A. Farmacología Humana. Masson- Salvat. 5ª Edición. 2008.

Hardman, J.G.; Limbird, L.E. Goodman y Gilman. Bases Farmacológicas de la Terapéutica. Mc Graw Hill Interamericana. 2 volúmenes. 10ª Edición. 2001.

Brunton, L; Parker, K; Blumenthal, D; Buxton, I. Goodman y Gilman. Manual de farmacología y terapéutica. Mc Graw Hill. 2009.

Lorenzo, P.; Moreno, A.; Leza, J.C.; Lizasoain, I.; Moro, M.A Velásquez. Farmacología básica y clínica. Ed. Panamericana, 17ª Edición. 2005.

Raffa, R; Rawls, S; Portyansky Beyzarov, E. Netter. Farmacología ilustrada. Elsevier Masson. 1ª Edición. 2008

López Castellano, A; Moreno Royo, L; Vilaagrasa Sebastián, V. Manual de Farmacología. Guía para El uso racional Del medicamento. Elsevier. 2006

Malgor, L.A.; Valsecia, M. Farmacología Médica. 2ª Edición. 2000. 5 volúmenes. Soporte electrónico disponible en: <http://med.unne.edu.ar/farmaco.html>

Neal, M.J. Farmacología médica en esquemas. CTM. Servicios Bibliográficos S.A. 4ª Edición. 2003.

PR Vademécum. 13ª Edición. E.C.S.A. Argentina. 2006.

El Manual Merk de Diagnóstico y Tratamiento. Harcourt. 10ª Edición. 1999.

Diccionario de Medicina Océano Mosby. 4ª Edición. 1999.

Stanley L Robins. Patología estructural y funcional. Editorial Interamericana. 1998. Bovill J. Engbers F.

Pharmacodynamics of drug action en: Bovill J. Howie M. eds. Clinical pharmacology for anaesthetists. 1st ed. London. W B Saunders, 1999: 35-43.

Ciccione G. Holdcroft A. Drugs and sex differences: a review of drugs relating to anaesthesia. Br J Anaesth. 1999; 82: 255-65.

Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000 Apr; 107(4):519-23.

Capilla Montes C, Bermejo Vicedo T. Eficacia y seguridad de misoprostol en obstetricia. Farm Hosp 2005; 29: 177-184

Carbonell JL, Varela L, Velazco A, Cabezas E, Fernandez C, Sanchez C. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1998;57:83-8.

Carbonell Esteve JL, Varela L, Velazco A, Tanda R, Sanchez C. 25 mg Or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial.

Gynecol Obstet Invest 1999;47:182-7.

Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod 2004;19:81-84.

Aronsson A, Fiala C, Stephansson O, Granath F, Watzter B, Schweer H, Gemzell-Danielsson K. Pharmacokinetic profiles up to 12h after administration of vaginal, sublingual and slow-release oral misoprostol. Hum Reprod 2007;22:1912-1918

World Health Organization. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532-537.

Uso de misoprostol en Ginecología y Obstetricia. Manual FLASOG. Tercera edición. 2013.